The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-20 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Tobacco === On April 7, 2019, Pritzker made Illinois the first state in the Midwest to adopt Tobacco 21. As part of his plan to fund capital projects, Pritzker raised the sales tax on cigarettes by $1.
== Stages of progress in nanotechnology == In 2005, Mihail Roco, one of the architects of the USA's National Nanotechnology Initiative, proposed four states of nanotechnology that seem to parallel the technical progress of the Industrial Revolution, of which productive nanosystems is the most advanced. 1. Passive nanostructures - nanoparticles and nanotubes that provide added strength, electrical and thermal conductivity, toughness, hydrophilic/phobic and/or other properties that emerge from their nanoscale structure. 2. Active nanodevices - nanostructures that change states in order to transform energy, information, and/or to perform useful functions. There is some debate about whether or not state-of-the art integrated circuits qualify here, since they operate despite emergent nanoscale properties, not because of them. Therefore, the argument goes, they don't qualify as "novel" nanoscale properties, even though the devices themselves are between one and a hundred nanometers. 3. Complex nanomachines - the assembly of different nanodevices into a nanosystem to accomplish a complex function. Some would argue that Zettl's machines fit in this category; others argue that modern microprocessors and FPGAs also fit. 4. Systems of nanosystems/Productive nanosystems - these will be complex nanosystems that produce atomically precise parts for other nanosystems, not necessarily using novel nanoscale-emergent properties, but well-understood fundamentals of manufacturing. Because of the discrete (i.e.
This is a conceptual leap that was quite different from Ibn al-Nafis' refinement of the anatomy and bloodflow in the heart and lungs." This work, with its essentially correct exposition, slowly convinced the medical world. However, Harvey was not able to identify the capillary system connecting arteries and veins; these were later discovered by Marcello Malpighi in 1661.
The lotus is often confused with the true water lilies of the genus Nymphaea, in particular N. caerulea, the "blue lotus". In fact, several older systems, such as the Bentham & Hooker system (which is widely used in the Indian subcontinent), refer to the lotus by its old synonym, Nymphaea nelumbo. While all modern plant taxonomy systems agree that this species belongs in the genus Nelumbo, the systems disagree as to which family Nelumbo should be placed in or whether the genus should belong in its own unique family and order. According to the APG IV system, N. nucifera, N. lutea, and their extinct relatives belong in Proteales with the protea flowers due to genetic comparisons. Older systems, such as the Cronquist system, place N. nucifera and its relatives in the order Nymphaeles based on anatomical similarities. According to the APG IV classification, the closest relatives of Nelumbo include the sycamores (Platanaceae).
29-30 January An ambush patrol of Company C, 1st Battalion, 7th Marines observed approximately 300 PAVN cross the Song Ky Lam River, 6 km west of Điện Bàn. The company called in artillery fire and then engaged the unit, with Company D, 5th Marines joining the action. A search of the area at dawn found 72 PAVN dead. The first M551 Sheridan Armored Reconnaissance Vehicles arrived in South Vietnam and were deployed by the 3rd Squadron, 4th Cavalry Regiment and the 1st Squadron, 11th Armored Cavalry Regiment.
Sources: en.wikipedia.org
In pharmacology, bioavailability is a subcategory of absorption and is the fraction (%) of an administered drug that reaches the systemic circulation. By definition, when a medication is administered intravenously, its bioavailability is 100%. However, when a medication is administered via routes other than intravenous, its bioavailability is lower due to intestinal epithelium absorption and first-pass metabolism. Thereby, mathematically, bioavailability equals the ratio of comparing the area under the plasma drug concentration curve versus time (AUC) for the extravascular formulation to the AUC for the intravascular formulation. AUC is used because AUC is proportional to the dose that has entered the systemic circulation. Bioavailability of a drug is an average value; to take population variability into account, deviation range is shown as ±. To ensure that the drug taker who has poor absorption is dosed appropriately, the bottom value of the deviation range is employed to represent real bioavailability and to calculate the drug dose needed for the drug taker to achieve systemic concentrations similar to the intravenous formulation. To dose without knowing the drug taker's absorption rate, the bottom value of the deviation range is used in order to ensure the intended efficacy, unless the drug is associated with a narrow therapeutic window. For dietary supplements, herbs and other nutrients in which the route of administration is nearly always oral, bioavailability generally designates simply the quantity or fraction of the ingested dose that is absorbed.
=== Variable contact rates === It is well known that the probability of getting a disease is not constant in time. As a pandemic progresses, reactions to the pandemic may change the contact rates which are assumed constant in the simpler models. Counter-measures such as masks, social distancing, and lockdown will alter the contact rate in a way to reduce the speed of the pandemic. In addition, Some diseases are seasonal, such as the common cold viruses, which are more prevalent during winter. With childhood diseases, such as measles, mumps, and rubella, there is a strong correlation with the school calendar, so that during the school holidays the probability of getting such a disease dramatically decreases. As a consequence, for many classes of diseases, one should consider a force of infection with periodically ('seasonal') varying contact rate
6 September: The Tāmaki Makaurau by-election is won by Te Pāti Māori candidate Oriini Kaipara. The Sealord Group proposes closing its coated fish factory in Nelson, potentially affecting 79 jobs. 7 September – During the New Zealand First party's annual conference held at Palmerston North, party leader Winston Peters campaigns on increasing compulsory KiwiSaver contributions to ten percent and requiring migrants to sign a values statement. Pro-greyhound racing and Palestinian solidarity protesters picket the event. 8 September: Fugitive father Tom Phillips is shot dead during a confrontation with Police in Piopio, Waikato. Police take one of his children into custody and launch a search for the remaining two unaccompanied minors. By evening, police find the two remaining children safe at a remote campsite. ANZ Bank New Zealand agrees to pay a record fine of NZ$3.25 million to the New Zealand Government after admitting it had breached fair dealing laws twice between 2012 and 2023. The murder trial of Korean mother Hakyung Yee commences, who is facing murder charges for the deaths of her two children. The primary school teachers' union, the New Zealand Educational Institute, rejects the Government's latest pay offer and commences voting on strike action. 9 September – Voting commences in the 2025 local elections. 10 September – The Court of Appeal of New Zealand declines to quash Scott Watson's convictions for the murders of Ben Smart and Olivia Hope, concluding that there had been no "miscarriage of justice" in relation to the prosecution's hair evidence and Mr.
Excitotoxicity Cell death caused by excessive stimulation by neurotransmitters such as glutamate, leading to calcium overload and neuronal damage. It is implicated in stroke and neurodegenerative diseases. Executive function A set of cognitive processes including working memory, flexible thinking, and self-control. Primarily associated with the prefrontal cortex. Exocytosis The process by which vesicles release their contents outside the cell. In neurons, it refers to the release of neurotransmitters into the synaptic cleft. Extracellular matrix A network of proteins and molecules outside cells
Sources: en.wikipedia.org
== Diagnosis == The only reliable way to determine whether a soft-tissue tumor is benign or malignant is through a biopsy. The two methods for acquisition of tumor tissue for cytopathological analysis are:
== Nomenclature == Family: glycosyltransferases, specifically the hexosyltransferases Systematic name: UDP-galactose D-galactosyltransferase Other names: hydroxylysine galactosyltransferase collagen galactosyltransferase collagen hydroxylysyl galactosyltransferase UDP galactose-collagen galactosyltransferase uridine diphosphogalactose-collagen galactosyltransferase UDPgalactose:5-hydroxylysine-collagen galactosyltransferase Pathway lysine degradation
==== Depression and suicidality ==== Isotretinoin is the only non-psychiatric drug on the FDA's top 10 list of drugs associated with depression and is also within the top 10 for suicide attempts. A black box warning for suicide, depression, and psychosis has been present on isotretinoin's packaging in the United States since 2005. In March 2018, European Medicines Agency issued a warning on a possible risk of neuropsychiatric disorders (such as depression, anxiety, and mood changes) following the use of oral retinoids, including isotretinoin, though the limitations of the available data did not allow them to establish whether this risk was due to the use of retinoids. A Swedish retrospective cohort study with 5756 patients showed a significantly increased risk of attempted suicides from 6 months after the treatment to around 2 years after the treatment. In 2012, a systematic review covering all articles in the literature related to isotretinoin, depression, and suicide, as well as articles related to class effect, dose-response, and biological plausibility found that the literature reviewed was consistent with an association of isotretinoin administration and depression and with suicide in a subgroup of vulnerable individuals. Following this systematic review, in a 2014 review a group of Australian dermatologists and psychiatrists collaborated on a set of recommendations for safe prescribing of isotretinoin. However, whether isotretinoin use is causally associated with mental illness remains controversial.
== Further reading == Moskin, Julia (August 19, 2014). "Brisket Is Worth the Wait". The New York Times. Retrieved March 17, 2015. Green, Aliza (2005). Field Guide to Meat. Philadelphia: Quirk Books. ISBN 1-931686-79-3.
=== Pain === Chest pain is one of the most common symptoms of acute myocardial infarction and is often described as a sensation of tightness, pressure, or squeezing. Pain radiates most often to the left arm, but may also radiate to the lower jaw, neck, right arm, back, and upper abdomen. The pain most suggestive of an acute MI, with the highest likelihood ratio, is pain radiating to the right arm and shoulder. Similarly, chest pain similar to a previous heart attack is also suggestive. The pain associated with MI is usually diffuse, does not change with position, and lasts for more than 20 minutes. The pain may be described as pressure, tightness, a knife-like sensation, tearing, or burning. In some individuals it may manifest as a sense of impending doom rather than typical pain, or pain may be absent entirely. Levine's sign, in which a person localizes the chest pain by clenching one or both fists over their sternum, has classically been thought to be predictive of cardiac chest pain, although a prospective observational study showed it had a poor positive predictive value. Typically, chest pain because of ischemia, be it unstable angina or myocardial infarction, lessens with the use of nitroglycerin, but nitroglycerin may also relieve chest pain arising from non-cardiac causes.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.